Literature DB >> 15671089

Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency.

Annamaria Colao1, Carolina Di Somma, Francesca Rota, Rosario Pivonello, Maria Cristina Savanelli, Stefano Spiezia, Gaetano Lombardi.   

Abstract

To explore early effects of GH treatment or deprivation on cardiovascular risk factors and carotid intima-media thickness (IMT), we designed this randomized, cross-over study in 34 adult patients with severe GH deficiency. At study entry, the patients were randomized into two groups (A and B); group A (n = 17) received appropriate replacement therapy including GH at standard doses for 6 months and then were withdrawn from GH for the subsequent 6 months; group B (n = 17) received appropriate replacement therapy excluding GH for 6 months with the addition of GH in the subsequent 6 months. After the first 6 months, we observed a significant increase in IGF-I levels and of high-density lipoprotein (HDL)-cholesterol together with a significant decrease in diastolic blood pressure, the total/HDL-cholesterol ratio, and C-reactive protein in the patients in group A, whereas vascular parameters did not significantly change. In the patients in group B, none of the parameters studied significantly changed. After 6 months of GH withdrawal in the patients in group A, a significant decrease in IGF-I levels, a significant increase in the total/HDL-cholesterol ratio and C-reactive protein, and a trend toward an impairment of carotid IMT and peak velocities were observed. In the patients in group B, the addition of GH to the standard replacement induced a significant increase in IGF-I levels together with a decrease in systolic and diastolic blood pressure, total cholesterol and total/HDL-cholesterol ratio, and C-reactive protein, and an increase in HDL-cholesterol levels with a trend toward an improvement of vascular parameters. At the end of the study, mean IMT was significantly lower than at baseline both in group A (from 0.88 +/- 0.28 to 0.85 +/- 0.27 mm, P = 0.0003) and in group B (from 0.83 +/- 0.21 to 0.80 +/- 0.20 mm, P = 0.003). In conclusion, 6 months of GH replacement has beneficial effects whereas 6 months of GH deprivation has detrimental effects on cardiovascular risk factors and atherosclerosis. These findings support the indication for GH replacement in severe GH deficiency adult patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671089     DOI: 10.1210/jc.2004-2247

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 2.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

3.  Effects of growth hormone withdrawal in obese premenopausal women.

Authors:  E Lin; M A Bredella; A V Gerweck; M Landa; D Schoenfeld; A L Utz; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2013-06       Impact factor: 3.478

4.  Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration.

Authors:  M Scacchi; E Valassi; A I Pincelli; L M Fatti; F Pecori Giraldi; P Ascoli; R Viarengo; B Cestaro; F Cavagnini; R Cazzola
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

Review 5.  Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Growth Horm IGF Res       Date:  2014-12-20       Impact factor: 2.372

6.  Testosterone and growth hormone improve body composition and muscle performance in older men.

Authors:  Fred R Sattler; Carmen Castaneda-Sceppa; Ellen F Binder; E Todd Schroeder; Ying Wang; Shalender Bhasin; Miwa Kawakubo; Yolanda Stewart; Kevin E Yarasheski; Jagadish Ulloor; Patrick Colletti; Ronenn Roubenoff; Stanley P Azen
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

7.  Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study.

Authors:  Karina Danilowicz; Oscar Domingo Bruno; Marcos Manavela; Reynaldo Manuel Gomez; Ariel Barkan
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Authors:  Janet Lo; Sung Min You; Bridget Canavan; James Liebau; Greg Beltrani; Polyxeni Koutkia; Linda Hemphill; Hang Lee; Steven Grinspoon
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

9.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

10.  Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans.

Authors:  Nino G Joy; Jennifer M Perkins; Maia Mikeladze; Lisa Younk; Donna B Tate; Stephen N Davis
Journal:  J Diabetes Complications       Date:  2016-07-04       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.